idasanutlin + venetoclax + rituximab

A combination therapy consisting of **idasanutlin** (an oral small-molecule MDM2 inhibitor that reactivates p53 tumor suppressor function), **venetoclax** (an oral small-molecule inhibitor of BCL-2 that promotes apoptosis in malignant B cells), and **rituximab** (a monoclonal antibody targeting CD20 expressed on B lymphocytes, leading to cell lysis and immune-mediated clearance). This combination is under clinical investigation for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The combination employs triple targeting—p53 pathway activation (idasanutlin), apoptosis induction (venetoclax), and direct B cell depletion (rituximab)—to overcome resistance mechanisms in aggressive lymphoid malignancies[1].